Publications by authors named "David Ladkani"

Claim this Profile
P
Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical research.
Iris Grossman, Volker Knappertz, Daphna Laifenfeld, Colin Ross, Ben Zeskind, David Ladkani

Prog Neurobiol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-daily glatiramer acetate decreases magnetic resonance imaging disease activity in Japanese patients with relapsing-remitting multiple sclerosis.
Takashi Yamamura, Natalia Ashtamker, David Ladkani, Toshiyuki Fukazawa, Hideki Houzen

Clin Exp Neuroimmunol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree.
Gary R Cutter, Volker Knappertz, Nissim Sasson, David Ladkani

BMC Neurol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition.
Tal Hasson, Sarah Kolitz, Fadi Towfic, Daphna Laifenfeld, Shlomo Bakshi, David Ladkani

J Neuroimmunol· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Alfacalcidol on multiple sclerosis-related fatigue: A randomized, double-blind placebo-controlled study.
Anat Achiron, Uri Givon, David Magalashvili, Mark Dolev, Sigal Liraz Zaltzman, David Ladkani

Mult Scler· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids.
Sarah Kolitz, Tal Hasson, Fadi Towfic, Jason M Funt, Shlomo Bakshi, David Ladkani

Sci Rep· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing the biological impact of glatiramer acetate with the biological impact of a generic.
Fadi Towfic, Jason M Funt, Kevin D Fowler, Shlomo Bakshi, Eran Blaugrund, David Ladkani

PLoS One· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glatiramer acetate treatment in PPMS: why males appear to respond favorably.
Jerry S Wolinsky, Tzippy Shochat, Sivan Weiss, David Ladkani,

J Neurol Sci· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The glatiramoid class of immunomodulator drugs.
Haim Varkony, Vera Weinstein, Ety Klinger, Jeffrey Sterling, Helena Cooperman, David Ladkani

Expert Opin Pharmacother· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.
Jerry S Wolinsky, Ponnada A Narayana, Paul O'Connor, Patricia K Coyle, Corey Ford, David Ladkani

Ann Neurol· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials.
Filippo Martinelli Boneschi, Marco Rovaris, Kenneth P Johnson, Aaron Miller, Jerry S Wolinsky, David Ladkani

Mult Scler· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-term correlations between clinical and MR imaging findings in relapsing-remitting multiple sclerosis.
Marco Rovaris, Giancarlo Comi, David Ladkani, Jerry S Wolinsky, Massimo Filippi

AJNR Am J Neuroradiol· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis